Cerevel Therapeutics Holdings, Inc. (CERE)

Market Cap	7.51B
Revenue (ttm)	n/a
Net Income (ttm)	-460.47M
Shares Out	182.20M
EPS (ttm)	-2.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,053,102
Open	41.15
Previous Close	41.35
Day's Range	40.95 - 41.29
52-Week Range	19.59 - 43.59
Beta	1.42
Analysts	Hold
Price Target	42.67 (+3.49%)
Earnings Date	Aug 1, 2024

About CERE

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selectiv...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 334
• Stock Exchange: NASDAQ
• Ticker Symbol: CERE

Analyst Forecast

According to 9 analysts, the average rating for CERE stock is "Hold." The 12-month stock price forecast is $42.67, which is an increase of 3.49% from the latest price.

Price Target

$42.67

(3.49% upside)

Analyst Consensus: Hold